Axicabtagene ciloleucel: Additional Ph I/II ZUMA-1 data

Data from 101 patients with chemorefractory aggressive B cell NHL in the open-label, U.S. and Israeli Phase I/II ZUMA-1 trial showed that a single IV infusion of axicabtagene ciloleucel led to an ORR of 82% and a complete response (CR) rate of 54%. At 6 months, the ORR and CR rates were 41% and 36%, respectively. The trial evaluated axicabtagene ciloleucel in patients with diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma, and primary mediastinal B cell lymphoma (PMBCL). In 77 patients with DLBCL, KTE-C19 led to an ORR of 82% and a CR rate of 49%. At 6 months, the ORR and CR rates were 36% and 31%, respectively. In 24 patients with transformed follicular lymphoma or PMBCL, KTE-C19 led to an ORR of 83% and a CR rate of 71%. At 6 months, the ORR and CR rates were 54% and 50%, respectively. Median OS has not yet been reached at a median follow-up of 8.7 months. Additional data will be presented at the American Association for Cancer Research meeting in Washington, D.C. in April. Kite has previously reported data from the trial (see BioCentury, Nov. 23, 2015; Dec. 14, 2015; June 20, 2016 & Oct. 3, 2016)...